ChetasiTalatiMD(She/Her)

PubMed

• 5 citations
  Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
  Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball
  Blood Advances. 2024-03-12
• 1 citations
  Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
  Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani
  Blood. 2023-03-23
• 24 citations
  Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
  Caner Saygin, Gregory Roloff, Christopher N Hahn, Rakchha Chhetri, Saar Gill
  Blood Advances. 2023-02-28

Abstracts/Posters

• Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of ...
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia
  Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all